Alkermes plc (NASDAQ:ALKS – Free Report) – Analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Alkermes in a note issued to investors on Thursday, February 13th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.22 for the quarter, down from their previous forecast of $0.27. HC Wainwright currently has a “Neutral” rating and a $46.00 target price on the stock. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Alkermes’ Q2 2025 earnings at $0.31 EPS and Q4 2025 earnings at $0.39 EPS.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%.
View Our Latest Stock Analysis on Alkermes
Alkermes Trading Down 0.3 %
NASDAQ ALKS opened at $35.89 on Monday. The company has a market cap of $5.81 billion, a PE ratio of 18.41, a PEG ratio of 1.83 and a beta of 0.49. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.25. The stock has a 50 day moving average of $30.40 and a 200-day moving average of $28.81.
Insider Transactions at Alkermes
In other news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the completion of the sale, the executive vice president now owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 323,608 shares of company stock valued at $10,854,725. 4.89% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of ALKS. Sanctuary Advisors LLC bought a new position in shares of Alkermes in the second quarter worth $228,000. CWM LLC increased its position in shares of Alkermes by 83.4% in the third quarter. CWM LLC now owns 14,547 shares of the company’s stock worth $407,000 after purchasing an additional 6,615 shares during the period. Creative Planning increased its position in shares of Alkermes by 51.7% in the third quarter. Creative Planning now owns 50,629 shares of the company’s stock worth $1,417,000 after purchasing an additional 17,264 shares during the period. Vontobel Holding Ltd. increased its position in shares of Alkermes by 128.9% in the third quarter. Vontobel Holding Ltd. now owns 56,261 shares of the company’s stock worth $1,575,000 after purchasing an additional 31,687 shares during the period. Finally, V Square Quantitative Management LLC bought a new position in shares of Alkermes in the third quarter worth $29,000. Institutional investors own 95.21% of the company’s stock.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
- Five stocks we like better than Alkermes
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- Investing in Commodities: What Are They? How to Invest in Them
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- 10 Best Airline Stocks to Buy
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.